Cargando…

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

BACKGROUND: This phase I dose-finding trial evaluated safety, efficacy and pharmacokinetics of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors, combined with platinum doublets in patients with advanced non-small cell lung cancer (NSCLC) an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kozloff, M F, Martin, L P, Krzakowski, M, Samuel, T A, Rado, T A, Arriola, E, De Castro Carpeño, J, Herbst, R S, Tarazi, J, Kim, S, Rosbrook, B, Tortorici, M, Olszanski, A J, Cohen, R B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494447/ https://www.ncbi.nlm.nih.gov/pubmed/22990652 http://dx.doi.org/10.1038/bjc.2012.406

Ejemplares similares

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
por: Martin, L P, et al.
Publicado: (2012)

Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours
por: Hoh, C K, et al.
Publicado: (2014)

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
por: Cella, D, et al.
Publicado: (2013)

ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups
por: Quinn, D.I., et al.
Publicado: (2021)

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
por: Escudier, B, et al.
Publicado: (2014)

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma
por: Atkins, Michael B, et al.
Publicado: (2015)

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
por: Wasan, H S, et al.
Publicado: (2009)

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
por: Rini, Brian I., et al.
Publicado: (2014)

Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer
por: Bondarenko, Igor M, et al.
Publicado: (2015)

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers
por: Pithavala, Y. K., et al.
Publicado: (2009)

Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor
por: Michael, M, et al.
Publicado: (2010)

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors
por: Michaelson, M. Dror, et al.
Publicado: (2019)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
por: Tortorici, Michael A., et al.
Publicado: (2010)

Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma
por: Murphy, Danielle A, et al.
Publicado: (2020)

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
por: Gross-Goupil, M, et al.
Publicado: (2018)

Axitinib/pembrolizumab: Tumour-lysis-syndrome: case report
Publicado: (2020)

Adaptive dosing and platinum–DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours
por: Veal, G J, et al.
Publicado: (2007)

Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma
por: Karakiewicz, Pierre I, et al.
Publicado: (2016)

Protocol for Identification and Removal of Doublets with DoubletDecon
por: DePasquale, Erica A.K., et al.
Publicado: (2020)

The Other Natural Two Higgs Doublet Model
por: Mrazek, J., et al.
Publicado: (2011)

A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses
por: Cohen, E. E. W., et al.
Publicado: (2014)

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet
por: Cottrill, Hope, et al.
Publicado: (2018)

The inert doublet model
por: Arias, C, et al.
Publicado: (2010)

Doublet final focus
por: Autin, B
Publicado: (1996)

On the $ doublet in $
por: Astner, G, et al.
Publicado: (1970)

Platinum-doublet chemotherapy for advanced gastroenteropancreatic neuroendocrine carcinoma: a systematic review and meta-analysis
por: Ohmoto, Akihiro, et al.
Publicado: (2022)

DoubletDecon: Deconvoluting Doublets from Single-Cell RNA-Sequencing Data
por: DePasquale, Erica A.K., et al.
Publicado: (2019)

Resolution of the major poliovirus capsid polypeptides into doublets
por: Vrijsen, R., et al.
Publicado: (1978)

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma
por: Gunnarsson, Orvar, et al.
Publicado: (2015)

Maximum entropy technique in the doublet structure analysis
por: Belashev, B Z, et al.
Publicado: (1998)

New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy
por: Koo, Dong-Hoe, et al.
Publicado: (2021)

Search for heavy neutral Higgs bosons in two-doublet models
por: Abreu, P, et al.
Publicado: (1994)

Baryogenesis in the Two-Higgs Doublet Model
por: Fromme, L, et al.
Publicado: (2006)

Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy
por: Hao, Desirée, et al.
Publicado: (2020)

Search for the neutral Higgs bosons of the MSSM and other two-doublet models
por: Décamp, D, et al.
Publicado: (1991)

Top-bottom doublet in the sphaleron background
por: Moreno, J M, et al.
Publicado: (1995)

Factors affecting platinum concentrations in human surgical tumour specimens after cisplatin.
por: Stewart, D. J., et al.
Publicado: (1995)

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets
por: Carter, Corey A., et al.
Publicado: (2016)

Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity
por: Fu, Ying, et al.
Publicado: (2022)

Emulsion sheet doublets as interface trackers for the OPERA experiment
por: Anokhina, A., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_uc3jiudib9vat9ejccai8oh3j6